A detailed history of Acadian Asset Management LLC transactions in Allakos Inc. stock. As of the latest transaction made, Acadian Asset Management LLC holds 2,168,594 shares of ALLK stock, worth $2.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,168,594
Previous 1,762,814 23.02%
Holding current value
$2.56 Million
Previous $1.76 Million 19.59%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.54 - $0.92 $219,121 - $373,317
405,780 Added 23.02%
2,168,594 $1.42 Million
Q2 2024

Aug 06, 2024

BUY
$1.0 - $1.45 $431,175 - $625,203
431,175 Added 32.38%
1,762,814 $1.76 Million
Q1 2024

May 10, 2024

BUY
$1.02 - $3.23 $1.28 Million - $4.07 Million
1,259,778 Added 1753.08%
1,331,639 $1.68 Million
Q4 2023

Feb 13, 2024

SELL
$1.72 - $3.18 $19,692 - $36,407
-11,449 Reduced 13.74%
71,861 $195,000
Q3 2023

Nov 13, 2023

SELL
$2.13 - $5.55 $1.06 Million - $2.76 Million
-497,790 Reduced 85.66%
83,310 $189,000
Q2 2023

Aug 07, 2023

BUY
$3.6 - $5.25 $1.31 Million - $1.91 Million
362,925 Added 166.35%
581,100 $2.53 Million
Q1 2023

May 11, 2023

SELL
$4.3 - $8.27 $1.75 Million - $3.36 Million
-406,665 Reduced 65.08%
218,175 $969,000
Q4 2022

Feb 14, 2023

SELL
$5.66 - $8.42 $2.42 Million - $3.6 Million
-428,005 Reduced 40.65%
624,840 $5.26 Million
Q3 2022

Nov 14, 2022

SELL
$3.02 - $6.12 $402,771 - $816,212
-133,368 Reduced 11.24%
1,052,845 $6.44 Million
Q3 2022

Nov 14, 2022

SELL
$3.02 - $6.12 $402,771 - $816,212
-133,368 Reduced 11.24%
1,052,845 $6.44 Million
Q2 2022

Aug 09, 2022

BUY
$2.6 - $6.14 $2.44 Million - $5.76 Million
938,670 Added 379.19%
1,186,213 $3.71 Million
Q1 2022

May 12, 2022

BUY
$5.08 - $9.81 $1.26 Million - $2.43 Million
247,543 New
247,543 $1.41 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $100M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.